Andreas Laustsen
@andreaslaustsen
Professor & Biotech Entrepreneur Antibody discovery | Toxinology | Snakebite envenoming | Infectious diseases | Microbiome | Antimicrobial resistance
ID: 788800790534160384
http://www.tropicalpharmacology.com 19-10-2016 17:55:38
1,1K Tweet
1,1K Followers
292 Following
Spot on Lone Frank: Mens vi gladeligt og gratis fodrer udenlandske techgiganter med dybt personlige data, er vi påfaldende nervøse for at overlade anonymiserede sundhedsdata til offentligt betalte forskere #sundpol weekendavisen.dk/2024-26/samfun…
Current antivenoms are expensive and have limited coverage. A new nanobody-based antivenom is cost-effective and requires smaller doses. This could drastically improve snakebite management. Luisa Torres spoke to Andreas Laustsen to learn more. ow.ly/rMQX50SzXyW
I'm happy to share a new article from Center for Antibody Technologies at DTU / DTU Bioengineering, just published in Illustreret Videnskab! We explore a new treatment for impotence inspired by #spider #venom, promising to enhance sexual health. Read: illvid.dk/medicin/laegem… Thanks to Eva, Nick, Jojo & Friis!
Excited to share that NOON Ventures has invested USD 4.3 million in Agrobiomics to bring our crop #biostimulants to the market! Thanks to both the BioInnovation Institute and DTU for helping create this spinout company from DTU Bioengineering! Read more: agfundernews.com/agrobiomics-la…
New popular science article from Center for Antibody Technologies at DTU / DTU Bioengineering published in Science Illustrated! "New drug against impotence: venomous spider could save your sex life": scienceillustrated.com/medicine/new-d… Thanks to my co-authors, Evangelia, Nick, Suthimon, and Emilie!
How can researchers launch viable startups & navigate between academia & the business world? Andreas Laustsen-Kiel (Andreas Laustsen), European Research Council (ERC) StG awardee, Danish member of the Young Academy of Europe (Young Academy of Europe (YAE)) explains in this nature piece. Eurodoc Marie Curie Alumni Association (MCAA)
Ever heard of a university "spin-in?" Andreas Laustsen describes how a biotech he co-founded struggled to develop commercially, despite meeting a clear societal need. go.nature.com/3zxEuxj